[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100371071":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":30,"locations":40,"responsibleParty":73,"collaborators":75,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":10,"eligibilityCriteria":91,"healthyVolunteers":88,"sex":92,"minAge":93,"maxAge":10,"enrollmentInfo":94,"targetDuration":10,"studyType":97,"phases":10,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Norwegian University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Glioma",null,"20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET\u002FMRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET\u002FMRI at baseline for comparison with 18F-FACBC.\n\n30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET\u002FMRI at treatment\u002Fbaseline and 1 month after radiosurgery.",[13],"Other: Diagnostic Amino acid PET\u002FMRI examination",{"label":15,"type":10,"description":16,"interventionNames":17},"Brain Metastases","Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET\u002FMRI at baseline, 1 month after surgery\u002Fstereotactic radiosurgery (St. Olavs Hospital\u002FUNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"Diagnostic Amino acid PET\u002FMRI examination",[15,9],[23,26],{"name":24,"affiliation":5,"role":25},"Live Eikenes, Phd","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":29},"Øystein Risa","Norwegian University for Science and Technology","STUDY_DIRECTOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Live Eikenes, PhD","CONTACT","0047 99568081","live.eikenes@ntnu.no",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Anna Karlberg, PhD","0047 40489126","anna.karlberg@ntnu.no",[41,53,61],{"facility":42,"status":43,"city":44,"state":10,"zip":10,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":10},"Haukeland universitetssykehus","NOT_YET_RECRUITING","Bergen","Norway","NO",{"type":48,"coordinates":49},"Point",[50,51],5.32415,60.39299,{"lat":51,"lon":50},{"facility":54,"status":43,"city":55,"state":10,"zip":10,"country":45,"countryCode":46,"cosmosGeoPoint":56,"geoPoint":60,"contacts":10},"Universitetssykehus Nord Norge","Tromsø",{"type":48,"coordinates":57},[58,59],18.95508,69.6489,{"lat":59,"lon":58},{"facility":62,"status":63,"city":64,"state":10,"zip":10,"country":45,"countryCode":46,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"St Olavs Hospital","RECRUITING","Trondheim",{"type":48,"coordinates":66},[67,68],10.39506,63.43049,{"lat":68,"lon":67},[71],{"name":72,"role":33,"phone":10,"phoneExt":10,"email":35},"Live Eikenes",{"type":74,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[76,78,80,82,84],{"name":77,"class":6},"St. Olavs Hospital",{"name":79,"class":6},"University of Bergen",{"name":81,"class":6},"Haukeland University Hospital",{"name":83,"class":6},"University of Tromso",{"name":85,"class":6},"University Hospital of North Norway","100371071","diagnostic-assessment-of-amino-acid-petmri-in-the-evaluation-of-glioma-and-brain-metastases-100371071",false,"NCT04111588","Diagnostic Assessment of Amino Acid PET\u002FMRI in the Evaluation of Glioma and Brain Metastases","Inclusion Criteria:\n\n* Inclusion criteria Glioma (LGG, HGG and recurrent HGG):\n\n  * Planned treatment for WHO grade II-IV diffuse glioma\n  * Adult patients (\\>18 years)\n  * Planned tissue sampling for histopathological diagnosis.\n  * KPS \\>60 (able to care for self)\n\nInclusion criteria Brain Metastasis:\n\n* Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases\n* Planned surgery: Suspicion of brain metastasis or known diagnosis\n* Stereotactic surgery: Known primary cancer\n* Adult patients (\\>18 years)\n* Estimated survival at least 3 months after inclusion\n\nExclusion Criteria:\n\n* Exclusion criteria (Glioma and Brain Metastasis):\n\n  * Pacemakers or defibrillators not compatible with 3T MRI\n  * No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits).\n  * Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist)\n  * Breastfeeding\n  * Weight \\> 120 kg","ALL","18 Years",{"count":95,"type":96},160,"ESTIMATED","OBSERVATIONAL","MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes and recurrences.\n\nAmino acid PET has demonstrated a great potential for defining true tumor volume, differentiate viable tumor tissue from postoperative changes or radiation necrosis, selection of biopsy site, non-invasive grading of gliomas and for treatment planning and therapy response assessment. By combining PET with MRI, the diagnostic accuracy can improve significantly for these patients. More research is however needed to compare the most promising amino acid PET tracers in patients with glioma, but also to assess the diagnostic value of amino acid PET in patients with different brain metastases, where the knowledge concerning the uptake characteristics is limited.\n\nThree of the most promising amino acid tracers (\\[11C\\]-methyl-methionine (11C-MET), \\[18F\\] fluoro-ethyl-tyrosin (18F-FET) and anti-1-amino-3-\\[18F\\]fluorocyclobutane-1-carboxylic acid (18F-FACBC)) will be evaluated in 3 substudies in this project; WP1 Aminoacid PET\u002FMRI in low and high grade glioma; WP2 Role of 11C-MET in high-grade glioma Gamma Knife® radiosurgery; and WP3 Amino acid PET in brain metastasis.\n\nThe main aim of the study is to improve diagnostic accuracy, histopathological tissue sampling, delineation of tumor extent and therapy response assessment in gliomas and brain metastases with amino acid PET\u002FMRI.",[100],"Brain Neoplasms",[102,103,104,105],"Diagnosis","Magnetic Resonance Imaging","Positron-Emission Tomography","PET-tracer","2025-06-17",{"date":108,"type":109},"2025-06-22","ACTUAL",{"date":111,"type":109},"2019-11-25",{"date":113,"type":96},"2027-12-31",{"name":5,"class":6},3]